|Podcasts|January 19, 2011

Build A Drug's Value in Early

Build a Drug's Value in Early

Mark Clein, President of United BioSource (UBC), discusses the company’s recent acquisition of Total Healthcare Group, a London-based consultancy on payer research, strategic planning and global value dossiers for the biopharma industry. Clein also discusses the current focus on comparative effectiveness, evidence-based research and value in medicines and how that impacts the Phase I through III development environment.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast
May 2nd 2025
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025
Thinking Big for Small and Mid-Sized Biotechs: How Applying Modeling and Simulation Technologies Can Improve Drug Development
January 6th 2023
The Evolving Relationship Between Sponsors and the Contract Research Organizations
December 8th 2022
The MDR: Navigating Europe’s New Standard for Medical Device Safety
October 25th 2022
The impact an eClinical Supply Chain Management platform can have on your next clinical trial
September 19th 2022

Trending on Applied Clinical Trials Online

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership

Viridian Therapeutics Completes Enrollment in Phase III Trial for Novel Monoclonal Antibody in Thyroid Eye Disease

© 2025 MJH Life Sciences^®

All rights reserved.